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Karolinska University Hospital, Stockholm, SwedenAbstract Lipoprotein-proteoglycan binding is an
early key event in atherosclerotic lesion formation
and thus conceivably could play a major role in
vasculopathy-driven chronic graft failure and car-
diovascular mortality in renal transplant recipients.
The present study investigated whether lipoprotein-
proteoglycan binding susceptibility (LPBS) of apoB-
containing lipoproteins and levels of the classical
atherosclerosis biomarker LDL-C were associated
with cardiovascular mortality (n ¼ 130) and graft
failure (n ¼ 73) in 589 renal transplant recipients who
were followed up from at least 1 year after trans-
plantation for 9.5 years. At baseline, LPBS was
significantly higher in patients who subsequently
developed graft failure than in those with a surviving
graft (1.68 ± 0.93 vs. 1.46 ± 0.49 nmol/mmol, P ¼ 0.001).
Cox regression analysis showed an association be-
tween LPBS and chronic graft failure in an age- and
sex-adjusted model (hazard ratio: 1.45; 95% CI,
1.14–1.85; P ¼ 0.002), but no association was observed
with cardiovascular mortality. LDL-C levels were not
associated with graft failure or cardiovascular mor-
tality. This study shows that measurement of
cholesterol retention outperformed the traditionally
used quantitative parameter of LDL-C levels in pre-
dicting graft failure, suggesting a higher relevance of
proatherogenic function than the quantity of apoB-
containing lipoproteins in chronic kidney graft
failure.
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This is an open access article under the CC BY license (http://creativecommons.org/licAtherosclerosis negatively impacts the prognosis of
renal transplant recipients (RTRs) in two ways, (i) in the
form of pre-existing, mostly complex atherosclerotic
lesions, which are the underlying pathology for CVD
and (ii) as de novo atherosclerotic lesion formation in
the graft, known as transplant vasculopathy (TV), the
single major cause for chronic graft failure (GF) (1–3).
Patients receiving kidney grafts often have a long-
standing history of end-stage renal disease with dial-
ysis treatment, which is per se associated with a 30- to
40-fold increase in age-adjusted CVD mortality (4).
After transplantation, CVD risk is still 4- to 6-fold
higher and is the leading cause of death in RTRs (4).
A decrease in renal function over time further con-
tributes to the increased risk. The substrate for this
chronic graft functional decline is TV, an atheroscle-
rotic process in the vasculature of the transplanted or-
gan, affecting 50% of allografts after 5 years and 90%
after 10 years (2, 3). Importantly, in RTRs, classical CVD
risk factors, such as levels of LDL-C or HDL-C, fail to
serve as predictive biomarkers either for CVD events or
for de novo atherosclerosis leading to TV-mediated
chronic GF (1, 3, 5). Thus, the identification of predic-
tive biomarkers represents an unmet clinical need in
this patient population. Recent studies indicated that
assays capturing the functional properties of HDL li-
poproteins might provide clinical information beyond
cholesterol levels within these, exemplified by HDL
cholesterol efflux capacity being able to predict CVD in
the general population (6, 7) and chronic GF in RTRs
(8), independent of HDL-C levels. However, throughout
the atherogenic process, especially LDL particles play a
central and pivotal role (9). Specifically, binding of LDL
particles to proteoglycans in the vessel wall is an early
key event in the initiation of atherosclerotic lesions, asJ. Lipid Res. (2021) 62 100083 1
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summarized in the now widely accepted response-to-
retention hypothesis of atherogenesis (10). However,
thus far, the concept that measures of LDL function-
ality can be used as predictive biomarkers has not been
widely explored. Especially, the susceptibility of LDL to
bind to vascular proteoglycans appears promising in
this respect. Therefore, in the present work, we inves-
tigated, whether in comparison to LDL-C levels, the
lipoprotein-proteoglycan binding susceptibility (LPBS)
of apoB-containing lipoproteins is prospectively asso-
ciated with the two clinically relevant atherosclerosis-
related outcomes in RTRs, CVD mortality on the one
hand and chronic GF on the other.MATERIALS AND METHODS
Study design and study population
For this prospective study, an established and well-
characterized patient cohort of adult RTR (Transplant-
Lines) was used (8, 11). Patients were recruited at the outpa-
tient clinic of the University Medical Center Groningen
between August 2001 and July 2003. To lessen the potential
confounding effect of early immune-mediated rejection,
patients were required to have, at inclusion, a functioning
graft for at least 1 year after transplantation. Exclusion
criteria were overt congestive heart failure, endocrine ab-
normalities other than diabetes mellitus, malignancies other
than cured skin cancer, and suspected acute infection. 606 of
847 eligible patients volunteered to participate and were
included in the cohort (72% consent rate). Nonparticipants
were compared with participants with regard to age, sex,
BMI, plasma creatinine, creatinine clearance, and protein-
uria, and no significant differences were found (8, 11).
Written informed consent was obtained from all partici-
pants. The institutional review board approved the study
protocol (METc2001/039), which complied with the Decla-
ration of Helsinki. The study is registered at ClinicalTrials.
gov with identifier NCT03272854 under the name “The
TransplantLines Insulin Resistance and Inflammation Bio-
bank and Cohort Study”.
Outcome measures and end points of the study
The main outcome measure of this study is LPBS. Pri-
mary end points are (i) death-censored GF, defined as re-
turn to dialysis therapy or retransplantation and (ii)
cardiovascular mortality, defined as deaths with the prin-
cipal cause of death being CV in nature, using codes
410–447 of the International Classification of Diseases,
ninth revision (12). If the status of a patient was unknown,
general practitioners or referring nephrologists were con-
tacted. Subjects’ status regarding survival and GF was
recorded until April 2012. Causes of death were available
until May 2009. One subject was lost to follow-up.
Baseline measurements and definitions
Transplant characteristics, such as subject demographics,
previous history, as well as date and type of transplantation,
were extracted from the Groningen Renal Transplant
Database. Smoking status and CVD history (considered
positive if participants previously had a myocardial infarc-
tion, transient ischemic attack, or cerebrovascular accident)2 J. Lipid Res. (2021) 62 100083were obtained using a self-report questionnaire at inclusion.
Medical records were consulted for information on use of
medication. Standard immunosuppressive regimen changed
over the years: from 1968 to 1989, prednisolone and azathi-
oprine (100 mg/day); from January 1989 to February 1993,
cyclosporine standard formulation (10 mg/kg; trough levels
of 175–200 μg/l in the first 3 months, 150 μg/l between 3 and
12 months after transplantation, and 100 μg/l thereafter)
and prednisolone (initially 20 mg/day, rapidly tapered to
10 mg/day); from March 1993 to May 1997, cyclosporine
microemulsion (10 mg/kg, trough levels as before) and
prednisolone; and from May 1997 onward, mycophenolate
mofetil (2 g/day) was added (13).
Blood samples were drawn at time of inclusion after an
8–12 h overnight fasting period. No specific antioxidant was
added at the time of blood draw; however, all samples con-
tained EDTA, a known antioxidant, and were handled in an
identical fashion. All standard laboratory measures, including
hemoglobin A1C (HbA1c), were performed at time of inclu-
sion. Concentrations of total cholesterol (TC) and HDL-C were
determined using the cholesterol oxidase-phenol amino-
phenazone method. Concentration of LDL-C was calculated
using the Martin Hopkins equation (14). apoA-I, apoB, and
lipoprotein (a) [LP(a)] were determined by nephelometry with
reagents for Dade Behring nephelometer systems (BN II,
Siemens, Marburg, Germany). The glycerol-3-phosphate
oxidase-phenol aminophenazone method was used to mea-
sure plasma triglycerides. Levels of plasma high-sensitive C-
reactive protein were assessed by ELISA (8). Plasma glucose
levels were determined using the glucose-oxidase method,
and plasma insulin was measured using an AxSYM auto-
analyzer. Levels of glycosylated HbA1c were assessed by high-
performance liquid chromatography (8). homeostasis model
assessment of insulin resistance was used to determine insulin
resistance by multiplying glucose (mmol/l) with insulin (μU/
ml) and dividing the result by 22.5 (15). Creatinine concen-
trations in plasma and urine were determined using a modi-
fied version of the Jaffé method. The estimated glomerular
filtration rate (eGFR) was calculated using the Chronic Kid-
ney Disease Epidemiology Collaboration formula (16); all
values included in the analyses were obtained at time point of
inclusion. Creatinine clearance was calculated from 24-h uri-
nary creatinine excretion and plasma creatinine. Total uri-
nary protein concentration was analyzed using the Biuret
reaction.
Proteinuria was defined as urinary protein excretion ≥0.5 g
per 24 h. The diagnosis of diabetes mellitus was made if
antidiabetic medication was used or fasting plasma glucose
concentration was ≥ 7.0 mmol/l or HbA1c was >6.5% (17). The
BMI was calculated by dividing the weight in kilograms by the
height in meters squared. Blood pressure was measured
automatically in 1 min intervals after a 6 min rest in the su-
pine position (Omron M4; Omron Europe BV, The
Netherlands), and the mean of three measurements was
taken.
The LDL particle number and average size were deter-
mined in EDTA plasma (n = 158 participants) by 1H-NMR
spectroscopy using a Vantera® NMR Clinical Analyzer as
previously described (Labcorp, Raleigh, NC) (18). Plasma
group IIA phospholipase A2 (sPLA2-IIA) was assessed in n =
40 participants with an ELISA (Cayman Chemical, Ann Arbor,
MI) according to the manufacturer’s instructions. Conjugated
dienes were determined in apoB-containing lipoproteins (n =
40 participants) by absorbance at 233 nm after lipid extraction
with dichloromethane/methanol (2:1, v/v) (19) using pre-
cipitates generated by polyethylene glycol-6000 precipitation
of apoB-containing lipoproteins as described (6). Values were
normalized for LDL-C levels.
Laboratory analysis of lipoprotein binding to
proteoglycans
EDTA plasma samples of 589 participants were available
for the laboratory analysis of this study. The plasma samples
were collected at baseline, placed on ice, centrifuged at 4◦C,
immediately stored at −80◦C, and left unthawed until anal-
ysis. The samples were stored from time of inclusion
until 2019.
To determine the binding susceptibility of lipoproteins to
proteoglycans, human aortic proteoglycans were isolated
from the intima-media of atherosclerotic human aortas (20),
and the glycosaminoglycan content of proteoglycans was
quantified as overall marker of proteoglycans (21). Then, wells
of polystyrene 96-well plates (Thermo Fisher Scientific) were
coated with 100 μl of proteoglycans (50 μg/ml in PBS) by in-
cubation at 4◦C overnight. Wells were blocked with 1% bovine
serum albumin in PBS for 1 h at 37◦C. Wells without proteo-
glycan coating served as controls for unspecific binding. To
measure lipoprotein binding to the immobilized pro-
teoglycans, 1 μl of plasma (derived from RTRs at baseline) was
added to the wells in a buffer containing 140 mmol/l NaCl,
2 mmol/l MgCl2, 5 mmol/l CaCl2, and 10 mmol/l MES, pH 5.5,
and incubated for 1 h at 37◦C. The wells were washed with
10 mmol/l MES-50 mmol/l NaCl, pH 5.5, and the amount of
bound TC was determined using the Amplex Red cholesterol
kit (Molecular Probes). Each sample was analyzed in duplicate
and the nonspecific binding in a single well had been blocked
by the blocking buffer. The nonspecific binding consistently
accounts for about 5% of the binding to the PG-coated wells.
The assay was performed over a duration of several weeks.
The day-to-day variation of the measurement is <15% and to
control for this, a control plasma sample is analyzed in each
plate. However, no drift in the assay was noted. The variation
between duplicate measurements carried out in separate mi-
crotiter well plates is 2.3%. To correct for interindividual
differences in proatherogenic lipoproteins in each individual
sample, the amount of bound TC was divided by the con-
centration of plasma LDL-C. Results are thus expressed as
nmol bound TC/mmol plasma LDL-C. This measure gives a
realistic reflection of the binding susceptibility of plasma
proatherosclerotic lipoproteins to proteoglycans in the arte-
rial vessel wall. More than 90% of TC that binds to lipopro-
teins from plasma has been shown to be associated with LDL
particles (21, 22).Statistical analysis
Baseline characteristics of the study population were
analyzed for gender-stratified tertiles of levels of bound TC/
plasma LDL-C (low, medium, and high). Normally distributed
continuous variables are depicted as the mean ± standard
deviation, whereas continuous variables with a skewed distri-
bution are given as the median [25th–75th percentile]. Cate-
gorical variables are summarized by absolute numbers
(percentages).
Baseline characteristics were tested for differences
among groups with low, medium, and high LPBS based on
sex-stratified tertiles. Baseline characteristics for normally
distributed continuous variables were tested for differences
among groups with one-way ANOVA. The Kruskal-Wallis
test was used to assess differences between groups for
continuous variables with a skewed distribution. GroupLipodifferences in categorical data were tested with Pearson chi-
squared test.
LPBS of subjects who reached the respective end points was
compared with values of subjects not reaching the end points
of the study by independent samples t test. Similarly, the LPBS
for males and females was computed using independent
samples t test. Subsequently, all characteristics with a P < 0.10
across gender-stratified tertiles of LPBS were entered into a
step-wise multivariable linear regression model with back-
ward elimination (P < 0.05) to identify variables indepen-
dently associated with LPBS.
Multivariable Cox regression was used to calculate hazard
ratios (HRs) and 95% CI for the primary end points. Adjust-
ment of potential confounders was used to assess the inde-
pendent association of LPBS with the end points chronic GF
and cardiovascular mortality. Potential confounders were
determined as known risk factors of chronic GF and CVD in
RTRs and included age, sex, eGFR, periods of acute rejection,
number of human leukocyte antigen mismatches, primary
renal disease, diabetes mellitus, BMI, dialysis time, type of
transplantation, use of calcineurin inhibitors, use of prolif-
eration inhibitors, use of statins, time between transplantation
and baseline, and donor age. Validity of proportional hazard
assumptions was tested using Schoenfeld residuals. Further-
more, subgroup analysis using interaction tests were per-
formed in which HRs were determined across categories of
baseline characteristics. For continuous variables, the median
value was used as cutoff. For the end point chronic GF, the
subject characteristics were sex (male vs. female), age (<52.1 vs.
>52.1 years), use of statins (yes vs. no), eGFR (<46.7 and
≥46.7 ml/min per 1.73 m2), and period of acute rejection (yes
vs. no).
To compare the relevance of the proposed novel func-
tionality parameter with a traditional quantitative parameter,
statistical analyses were repeated for plasma concentration of
LDL-C at baseline and results were compared with those of
LPBS.
Two-sided P-values <0.05 were considered to indicate sta-
tistical significance. All statistical analyses and visualization of
data were conducted using STATA® Statistical Software,
Release 15.1 (StataCorp, College Station, TX).
RESULTS
In this longitudinal follow-up study, the LPBS was
measured in 589 RTRs. Individual LPBS values were
expressed as the ratio between proteoglycan-bound
cholesterol and plasma LDL-C levels (nmol/mmol).
Baseline characteristics according to sex-stratified ter-
tiles of LPBS are summarized in Table 1. The concen-
trations of TC, LDL-C, apoA-I (each P < 0.001),
triglycerides (P = 0.004), apoB (P = 0.012), and the LDL-
C/apoB ratio (P < 0.001) decreased significantly with
increasing tertiles of LPBS. Systolic blood pressure (P =
0.04) and BMI (P = 0.015) showed a significant inverse
association with binding susceptibility, but for other
potential cardiovascular risk factors including age, his-
tory of cardiovascular events, diabetes mellitus, tobacco
abuse, plasma triglycerides, and HDL-C, no relationship
with LPBS was evident.
Subsequently, backward multiple linear regression
analysis was used to assess which variables are de-
terminants of LPBS in RTRs (Table 2). Theprotein-proteoglycan binding and kidney graft failure 3
TABLE 1. Baseline characteristics according to sex-stratified tertiles of lipoprotein-proteoglycan binding susceptibility
Tertiles of Lipoprotein-Proteoglycan Binding Susceptibility (Bound TC/LDL-C)
PFirst (n = 197) Second (n = 196) Third (n = 196)
Outcome parameter
Lp-PG binding susceptibility, nmol/mmol 1.04 (0.94, 1.01) 1.29 (1.21, 1.34) 1.72 (1.64, 1.88) <0.001
Recipient demographics
Age, years 54.1 (43.9, 60.9) 52.8 (42.3, 61.0) 50.7 (41.5, 59.8) 0.099
Male gender, n (%) 109 (55.1%) 108 (55.1%) 108 (55.1%) 1.00
Current smoking, n (%) 71 (35.9%) 82 (42.5%) 81 (41.3%) 0.36
Body composition
BMI, kg/m2 26.8 ± 4.4 25.8 ± 4.2 25.6 ± 4.2 0.015
Waist circumference, men, cm 101.4 ± 11.8 99.0 ± 12.6 98.9 ± 12.8 0.23
Waist circumference, women, cm 95.0 (85.5, 104.5) 91.5 (81.0, 101.0) 93.5 (82.0, 104.0) 0.21
Waist-hip ratio, women 0.91 (0.85, 1.00) 0.90 (0.85, 0.97) 0.94 (0.85, 1.02) 0.068
Waist-hip ratio, men 1.02 (0.96, 1.07) 1.00 (0.95, 1.08) 1.02 (0.96, 1.08) 0.25
Lipids
TC, mmol/l 5.89 ± 1.10 5.69 ± 1.07 5.28 ± 1.00 <0.001
LDL-C, mmol/l 3.72 ± 0.97 3.64 ± 0.94 3.29 ± 0.96 <0.001
HDL-C, mmol/l 1.12 ± 0.34 1.11 ± 0.30 1.05 ± 0.33 0.054
apoA-I, g/l 1.57 (1.39, 1.78) 1.59 (1.41,1.78) 1.45 (1.29,1.65) <0.001
apoB, g/l 1.10 (0.96, 1.24) 1.06 (0.93, 1.23) 1.01 (0.90, 1.21) 0.012
Triglycerides, mmol/l 2.21 (1.57, 2.92) 1.87 (1.41, 2.40) 1.82 (1.29, 2.41) 0.004
LDL-C/apoB 3.52 ± 0.94 3.35 ± 0.56 3.08 ± 0.71 <0.001
CVD history
Myocardial infarction, n (%) 14 (7.1%) 14 (7.2%) 20 (10.3%) 0.43
TIA/CVA, n (%) 14 (7.1%) 9 (4.6%) 9 (4.6%) 0.47
Systolic blood pressure, mmHg 152.5 (139.0, 167.0) 150.0 (137.0, 167.0) 149.0 (132.5, 163.0) 0.037
Medication
Antihypertensive drugs, n (%) 177 (89.4%) 166 (84.7%) 171 (87.2%) 0.38
Calcineurin inhibitors, n (%) 151 (76.3%) 160 (81.6%) 151 (77.0%) 0.38
Proliferation inhibitors, n (%) 142 (71.7%) 140 (71.4%) 152 (77.6%) 0.30
Use of statins, n (%) 100 (50.5%) 105 (53.6%) 91 (46.4%) 0.37
Glucose homeostasis
Glucose, mmol/l 4.65 (4.20, 5.14) 4.45 (4.08, 5.02) 4.52 (4.10, 4.88) 0.22
HbA1c, % 6.30 (5.90, 7.10) 6.40 (5.80, 6.90) 6.40 (5.80, 7.003) 0.44
HOMA-IR 2.31 (1.62, 3.45) 2.33 (1.64, 3.31) 2.29 (1.55, 3.80) 0.89
Diabetes mellitus, n (%) 34 (18.5%) 30 (16.5%) 30 (16.0%) 0.79
C-reactive protein, mg/l 2.08 (0.95, 4.76) 1.82 (0.68, 4.49) 2.32 (0.76, 5.43) 0.55
Donor demographics
Age, years 37.0 (22.0, 49.0) 35.5 (23.5, 48.0) 41.0 (24.0, 52.0) 0.27
Male gender, n (%) 109 (55.3%) 110 (56.4%) 102 (52.3%) 0.70
Living kidney donor, n (%) 26 (13.1%) 25 (12.8%) 27 (13.8%) 0.96
Number of HLA mismatches 1.00 (0.00, 2.00) 1.00 (0.00, 2.00) 1.00 (0.00, 2.00) 0.64
(Pre)transplant history
Acute rejection, n (%) 92 (46.5%) 90 (45.9%) 83 (42.3%) 0.67
Dialysis time, month 26.0 (13.0, 47.0) 30.0 (17.0, 48.0) 27.0 (12.0, 52.0) 0.35
Time between Tx and inclusion, month 80.5 (37.0, 149.0) 70.0 (28.5, 134.0) 67.0 (34.0, 117.0) 0.11
Renal allograft function
eGFR, ml/min/1.73 m2 46.3 ± 15.2 47.4 ± 15.2 47.1 ± 16.9 0.78
Urinary protein excretion, g/24 h 0.20 (0.00, 0.50) 0.20 (0.00, 0.50) 0.30 (0.20, 0.60) 0.13
Proteinuria ≥0.5 g/24 h, n (%) 50 (25.3%) 54 (27.8%) 62 (31.6%) 0.37
CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HOMA-IR, Homeostatic Model
Assessment for Insulin Resistance; HLA, human leukocyte antigen; Lp, lipoprotein; PG, proteoglycan; TC, total cholesterol; TIA, transient
ischemic attack; Tx, transplantation
Normally distributed continuous variables are depicted as the mean ± standard deviation, continuous variables with a skewed distri-
bution are given as the median [25th–75th percentile], and categorical variables are summarized by absolute numbers (percentages). Dif-
ferences between tertiles of lipoprotein-proteoglycan binding susceptibility were tested using one-way ANOVA for normally distributed
continuous variables, Kruskal-Wallis test for continuous variables with a skewed distribution, and Pearson's chi-squared test for categorical
variables.concentration of TC (standardized β = −0.24, P <
0.001) and apoA-I (standardized β = −0.16, P < 0.001)
was inversely associated with LPBS. Model R2 was
0.10.
To further explore factors associated with LPBS, we
first correlated the LDL-C/apoB ratio as an, allowedly,
relatively crude but easy to calculate measure of the
LDL size with LPBS. Previously, a smaller size of LDL
particles had been identified as a determinant of4 J. Lipid Res. (2021) 62 100083increased binding to proteoglycans (23). Surprisingly,
an overall significant positive correlation was observed
in the RTR (r = 0.159, P < 0.001). To gain more insight,
we used NMR lipoprotein particle number and sizing
data that were available for n = 158 participants in our
study. Interestingly, only small LDL had a positive
correlation with LPBS (r = 0.20, P = 0.01), whereas me-
dium- (r = −0.07, not significant) or large-sized LDL
particles (r = 0.03, P = not significant) did not correlate
TABLE 3. Comparison between the association of either LDL
function (LPBS) or mass levels of LDL-C with cardiovascular
mortality
LPBS LDL-C Concentration
HR [95% CI] P HR [95% CI] P
Model 1 0.70 [0.38–1.30] 0.26 0.97 [0.75–1.25] 0.81
Model 2 0.74 [0.41–1.34] 0.32 0.98 [0.76–1.27] 0.89
Model 3 0.76 [0.41–1.39] 0.37 1.03 [0.80–1.32] 0.82
Model 4 0.74 [0.41–1.34] 0.32 0.97 [0.75–1.25] 0.80
Model 5 0.76 [0.42–1.38] 0.36 1.00 [0.77–1.29] 0.98
Model 6 0.76 [0.41–1.37] 0.36 1.00 [0.78–1.30] 0.97
Model 7 0.73 [0.40–1.35] 0.33 0.99 [0.76–1.28] 0.92
Model 8 0.72 [0.40–1.32] 0.29 0.99 [0.76–1.28] 0.93
HR, hazard ratio; LPBS, lipoprotein-proteoglycan binding
susceptibility.
Model 1: crude; model 2: adjusted for age and sex; model 3:
model 2+ adjustment diabetes mellitus; model 4: model 2+ adjust-
ment for BMI; model 5: model 2+ adjustment for dialysis time and
time between transplantation and inclusion; model 6: model 2+
adjustment for type of transplantation and donor age; model 7:
model 2+ adjustment for use of calcineurin inhibitors and prolif-
eration inhibitors; model 8: model 2+ adjustment for use of statins.
TABLE 4. Comparison between the association of either LDL
function (LPBS) or mass levels of LDL-C with chronic graft failure
LPBS LDL-C Concentration
HR [95% CI] P HR [95% CI] P
Model 1 1.87 [1.24–2.84] 0.003 1.13 [0.91–1.41] 0.25
Model 2 1.84 [1.21–2.81] 0.004 1.13 [0.91–1.41] 0.26
Model 3 1.85 [1.22–2.83] 0.003 1.15 [0.93–1.42] 0.20
Model 4 1.25 [0.85–1.82] 0.25 0.97 [0.78–1.20] 0.76
Model 5 1.85 [1.22–2.81] 0.004 1.14 [0.91–1.43] 0.24
Model 6 1.86 [1.23–2.83] 0.003 1.13 [0.90–1.42] 0.28
Model 7 1.89 [1.24–2.89] 0.003 1.13 [0.90–1.41] 0.29
Model 8 1.75 [1.15–2.69] 0.010 1.14 [0.90–1.45] 0.27
HR, hazard ratio; LPBS, lipoprotein-proteoglycan binding
susceptibility.
Model 1: crude; model 2: adjusted for age and sex; model 3:
model 2 + adjustment for use of statins; model 4: model 2 +
adjustment for estimated glomerular filtration rate; model 5: model
2 + adjustment for period of acute rejection; model 6: model 2 +
adjustment for number of human leukocyte antigen mismatches,
primary renal disease and period of acute rejection; model 7: model
2+ adjustment for dialysis time and time between transplantation
and baseline; model 8: model 2+ adjustment for type of trans-
plantation and donor age.
TABLE 2. Predictors of lipoprotein binding susceptibility
β 95% CI Standardized β P
Total cholesterol −0.94 −0.12, −0.06 −0.24 <0.001
apoA-I −0.24 −0.35, −0.12 −0.16 <0.001
All variables with P < 0.1 between tertiles were entered into a
stepwise linear regression with backward elimination.with LPBS. Because oxidative modification had been
shown to decrease binding of apoB-containing lipo-
proteins to proteoglycans (24), we measured in a subset
of our cohort (n = 40) the conjugated diene content in
these particles and correlated the result with LPBS.
Consistent with previous reports, also in RTRs, a sig-
nificant negative correlation between conjugated di-
enes and LPBS was observed (r = −0.46, P = 0.003). In
addition, enzymatic modification by sPLA2-IIA was
reported to increase binding of LDL to proteoglycans
(23). Also, this result could be replicated in our cohort
because plasma levels of sPLA2-IIA correlated posi-
tively with LPBS (r = 0.42, P = 0.016, n = 40). Because it
has been previously demonstrated that Lp(a) is
increased among patients with a low eGFR, (25) which
in turn leads to a higher binding affinity to pro-
teoglycans (26), we measured Lp(a) levels in our study
population. Lp(a) was not correlated with LPBS
(r = −0.06, P = 0.13). Furthermore, an adjusted Cox
regression with Lp(a) as independent variable showed
that there is no significant association between Lp(a)
levels and GF (HR = 1.11, P = 0.25).
Data concerning specific causes of death were avail-
able for a median follow-up of 7 years. Of 130 (22%)
patients who died in this period, 68 did so because of
confirmed cardiovascular causes (12% of the total study
population, 52% of the deceased patients). Furthermore,
29 (5% of the total study population, 22% of the
deceased patients) patients died from malignancy, 23
(4% of the total study population, 18% of the deceased
patients) from an infectious death, and 10 (2% of the
total study population, 7% of the deceased patients)
from other causes. During the median follow-up of
9.5 years for GF, a total of 73 (13%) subjects experienced
this end point.
At baseline, LDL-C as well as LPBS were comparable
between survivors and deceased RTRs, with respect to
cardiovascular mortality (LDL-C: 3.90 ± 1.0 vs. 3.88 ±
1.0 mmol/l, P = 0.87; LPBS: 1.34 ± 0.42 vs. 1.29 ±
0.5 nmol/mmol, P = 0.33). While baseline LDL-C levels
were also similar in patients developing GF or not (4.03
± 1.38 vs. 3.88 ± 0.91 mmol/l, P = 0.22), LPBS was
significantly higher in patients who subsequently
developed GF than in those with a surviving graft (1.47
± 0.63 vs. 1.32 ± 0.39 nmol/mmol, P = 0.003).
Cox regression analysis revealed that neither LPBS
nor the classical biomarker LDL-C was associated with
CVD mortality (Table 3); this conclusion remained
valid after adjustment for a number of potential
confounding factors in different statistical models.LipoHowever, Cox regression analysis showed a prospec-
tive association between LPBS and chronic GF (HR,
1.87; 95% CI, 1.24–2.84; P = 0.003, Table 4, model 1).
Adjusting for age and sex did not considerably reduce
this association (HR, 1.84; 95% CI, 1.21–2.81; P = 0.004,
Table 4, model 2).
Comparably, adjustment for a number of other
potentially impacting factors, namely the use of statins,
periods of acute rejection, number of HLA mismatches,
primary renal disease, dialysis time, time between
transplantation and inclusion, type of transplantation,
and donor age did not appreciatively change the sig-
nificance of the prospective association. However, after
additional adjustments for eGFR, significance was lost
(HR, 1.25, 95% CI, 0.85–1.82; P = 0.25, Table 4, model 7).
We attempted to further delineate the relationship ofprotein-proteoglycan binding and kidney graft failure 5
LPBS and eGFR. Pearson’s correlation coefficients
showed that there is no significant correlation between
eGFR and LPBS (r = −0.03, P = 0.52). Then, an inter-
action term was computed and the association with GF
was assessed (HR = 0.99, P = 0.40). This showed that
there is no significant interaction between eGFR and
LPBS.
In contrast to these findings with respect to the
functional read-out of LPBS, LDL-C levels were not
associated with GF, neither in univariate nor in all
computed multivariable Cox regression models
(Table 4).
Cox regression analyses were repeated with crude
proteoglycan binding. The results were not substan-
tially different with regard to the normalized marker
of LPBS (supplemental Tables S1 and S2).
As shown in Fig. 1, the association of LPBS with
chronic GF was not different for males versus fe-
males (P for interaction = 0.12), subjects with high
versus low age (P for interaction = 0.38), use of statins
versus no use of statins (P for interaction = 0.67),
high versus low eGFR (P for interaction = 0.17), or
period of acute rejection versus no period of acute
rejection (P for interaction = 0.45). However, for the
association of LPBS with CVD mortality, there was an
interaction with the use of calcineurin inhibitors
versus no use of calcineurin inhibitors (P for
interaction = 0.03), indicating that the relationship of
LPBS with CVD risk is stronger in subjects that use
calcineurin inhibitors.Fig. 1. Hazard ratios for the association of LDL function (LPBS)
teristics. eGFR, estimated glomerular filtration rate; LPBS, lipoprot
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The results of this study demonstrate that beyond the
static measurement of circulating LDL-C levels, func-
tional metrics determining lipoprotein retention to
proteoglycans such as LPBS can provide useful clinical
information. Specifically, we show that in RTRs, LPBS
was prospectively associated with chronic GF, a mani-
festation of de novo atherosclerosis, but not with CVD
death, largely a consequence of preexisting, complex
atherosclerotic lesions. We interpret these findings as
being consistent with the response-to-retention hy-
pothesis of atherosclerotic lesion formation (10). In
contrast, LDL-C was neither associated with incident
CVD mortality nor with chronic GF.
Although RTRs have a substantially elevated risk
for atherosclerosis-related disease, classical bio-
markers such as LDL-C or HDL-C levels fail to serve as
predictors (1, 3, 5). Thus, the identification of patients
at risk to develop either CVD events or accelerated
chronic GF represents an unmet clinical need. Dy-
namic functional tests for proatherogenic properties
of apoB-containing lipoproteins might offer a real-
istic chance to fill this current gap. Mechanistically,
RTRs have an increased proinflammatory and
oxidative stress load (27–29) that could conceivably
contribute to modify apoB-containing lipoproteins in
a way that they bind with higher affinity to vascular
proteoglycans. However, the precise molecular
mechanisms of this deserves further research.with incident graft failure, by several participant level charac-
ein-proteoglycan binding susceptibility.
Although we consistently observed that a high LPBS is
associated with measures of small LDL particles (NMR
as well as LDL-C/apoB ratio), high LPBS was also
associated with lower triglycerides. Given the inverse
correlation between triglycerides and small LDL in
the general population, especially the determinants of
triglyceride metabolism in the setting of RTRs need to
be better understood because this specific patient
group potentially experiences the combined impact
of kidney (dys)function, pre-existing disturbances in
metabolism such as insulin resistance and immuno-
suppressive medication. It also appears relevant to
include in such studies measures of oxidation in li-
poproteins of different sizes because small LDLs bind
better to proteoglycans but are on the other hand also
more susceptible to oxidative modification (30), which
would inhibit such binding (24). A multimodal
approach covering a multitude of different poten-
tially impacting factors could possibly help elucidate
the perceived complex interaction of different pro-
cesses and modifications relevant for the binding of
lipoproteins to proteoglycans in RTRs. Conversely,
and not addressed in the present work, the function
and/or quantity (and hence atherogenicity) of pro-
teoglycans could be altered as well in RTRs. Also here,
important impacting factors are inflammation and
oxidative stress. Oxidized LDL particles stimulate the
production of modified proteoglycans with elongated
chains, which consequently have a higher ability to
retain LDL (31, 32). It is conceivable that a multipli-
cative effect of modifications in both lipoproteins and
proteoglycans will lead to an even further enhanced
binding susceptibility and subsequently increased
atherosclerotic lesion formation. Research in rats
found that expression of perlecan, a basement
membrane-type heparan sulfate proteoglycan, is
significantly increased in renal allografts after
experimental transplantation, compared with non-
transplanted control kidneys and isografts (33). The
proteoglycan expression correlated with the severity
of tissue remodeling and impaired graft function (33).
This underlines, although challenging in clinical
routine, the potential benefits of including pro-
teoglycans present in the allograft’s extracellular
matrix in individual TV risk analyses.
Potential therapeutic intervention options to
decrease the interaction between LDL and pro-
teoglycans are thus far limited. In vitro, glucosamine
has been indicated to result in the production of pro-
teoglycans by smooth muscle cells with a reduced
binding capacity for LDL (34). However, dietary
glucosamine supplementation resulted in increased
atherosclerotic lesion formation in preclinical models
limiting the applicability of such an approach (35, 36).
Statins were shown to have a dual effect, decreasing
LDL-proteoglycan binding (21), as well as the produc-
tion of proteoglycans with reduced affinity to LDL (37).
However, in our patients, statin use was not associatedLipowith any change in LPBS. Finally, measures to enrich
LDL in cholesteryl oleate such as canola oil appear to
reduce the binding of LDL to proteoglycans (38), but
prospective clinical studies addressing this concept are
not available.
A potential limitation of the current work is that
this study is from a single center in the North of the
Netherlands, thus representing a population with a
relatively homogenous and also narrow Caucasian
genetic background. Further replication would be
required to inform, if our results are generalizable. In
addition, although TransplantLines is one of the
largest prospective renal transplantation cohorts, the
number of participants is still limited, thus impacting
predictive power. Future longitudinal research also
needs to address if and in which direction the rela-
tionship of LPBS with graft function is causative.
Next to our assumption that increased LPBS worsens
graft function, it could mechanistically also be envi-
sioned that a worsening graft function results in
increased LDL modifications and thereby more LDL-
proteoglycan binding (39). After all, a decreased eGFR
is to date the strongest predictor for incident GF (40).
To gain more mechanistic insights and distinguish
lipid-driven from immune-mediated events (or eluci-
date an interdependency of these), it would be valu-
able to carry out serial histological evaluations of the
vasculature of kidney grafts; however, due to the
invasive nature of such work, respective studies are
only possible to be carried out in preclinical models.
Furthermore, although EDTA (a known antioxidant
in addition to being an anticoagulant) plasma was
used, sample generation and storage were similar for
all patients and the assay was performed in an iden-
tical fashion for all samples using internal controls, a
certain degree of oxidation cannot be formally
excluded. In addition, despite differences in storage
time being minor as opposed to time until the assay
was performed, still samples were stored for a large
number of years before analysis and different storage
length of the samples might have a potential effect.
Furthermore, the clinical implementation of LPBS as
a biomarker is at this point difficult due to logistic
challenges and lack of standardization; overcoming
these represents a future challenge. With respect to
the chosen assay setup, we would like to point out that,
although the use of isolated LDL in proteoglycan
binding studies revealed important pathophysiolog-
ical information (10, 22, 39), the aim of our present
work was to set up an assay that can be performed in
large cohorts and, if proven useful, be further
developed for routine clinical chemistry laboratories.
However, feasibility challenges of routine LPBS
studies still include a lack of availability of sufficient
amounts of standardized arterial proteoglycans, as
well as using isolated LDL in the setting of a clinical
test. To address the latter issue, we also used human
plasma per unit volume. This procedure has theprotein-proteoglycan binding and kidney graft failure 7
advantage that no previous information regarding the
samples is required and no isolation of a specific class
of lipoproteins needs to be carried out that could
potentially also impact lipoprotein composition or
function. Importantly, another advantage of the
chosen setup is that any potential factors in plasma,
which could influence the interaction of LDL with
proteoglycans, are still present.
In summary, the present study indicates that LPBS as
a dynamic test for the individual proatherogenicity of
LDL particles is associated with incident GF. This asso-
ciation was particularly pronounced in patients with a
low eGFR. Our work suggests that focusing on the
interaction of lipoproteins with extracellular matrix
components could lead to the identification not only of
useful personalized predictive biomarkers but also of
potential pharmacological intervention targets.
Thereby, unmet clinical needs in the patient population
of RTR could be successfully addressed. The goal
would be to reduce lipid deposition in the vascular wall
of coronary arteries and kidney grafts to prevent
chronic GF and possibly also CVD events.
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